草稿:3-甲基甲卡西酮
臨床資料 | |
---|---|
ATC碼 |
|
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 口服: 5–9%[2] |
血漿蛋白結合率 | 低[2] |
藥物代謝 | 肝 |
生物半衰期 | 50分 (豬)[2] |
識別資訊 | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
化學資訊 | |
化學式 | C11H15NO |
摩爾質量 | 177.25 g·mol−1 |
3D模型(JSmol) | |
熔點 | ± 0.2°C |
| |
|
3-甲基甲卡西酮(亦稱 3-MMC 或 3-Methylmethcathinone),是一種卡西酮衍生物家族的設計毒品。3-MMC 是一種單胺轉運體底物(一種受單胺轉運體作用的物質),能有效釋放和抑制多巴胺和去甲腎上腺素的再攝取,並顯示出適度的5-羥色胺釋放活性。[3] [4] [2] [1] [5]
- ^ 1.0 1.1 News: March 2023 – UNODC: Seven NPS "scheduled" at the 66th Session of the Commission on Narcotic Drugs. United Nations Office on Drugs and Crime (UNODC). United Nations Office on Drugs and Crime. [29 May 2024].
- ^ 2.0 2.1 2.2 2.3 Shimshoni JA, Britzi M, Sobol E, Willenz U, Nutt D, Edery N. 3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. Journal of Psychopharmacology. June 2015, 29 (6): 734–43. PMID 25804420. S2CID 26012927. doi:10.1177/0269881115576687.
- ^ Preedy V. Neuropathology of Drug Addictions and Substance Misuse Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects 2. London: King's College. 2016年4月26日. ISBN 978-0-12-800212-4.
- ^ {{cite journal |vauthors=Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME |date=May 2018 |title=Pharmacological profile of mephedrone analogs and related new psychoactive substances |url=https://edoc. unibas.ch/57357/1/20170920120908_59c23e44b5f0e.pdf |journal=Neuropharmacology |volume=134 |issue=Pt A |pages=4-12 |doi=10.1016/j.neuropharm.2017
- ^ 3-Methylmethcathinone (3-MMC) Critical Review Report (PDF). World Health Organization. (原始內容 (PDF)存檔於2021-11-11).